摘要
目的:检测NUSAP1在浆液性卵巢癌及正常卵巢组织中的表达情况,研究NUSAP1的表达与浆液性卵巢癌临床病理因素的关系及对预后的临床意义。方法:利用TCGA数据库分析NUSAP1 mRNA的表达情况。应用免疫组织化学方法检测NUSAP1蛋白在115例浆液性卵巢癌及62例正常卵巢组织中的表达。利用Kaplan-Meier plotter数据库分析NUSAP1 mRNA表达对卵巢癌患者的预后价值。Cox回归模型进行多因素生存分析。结果:在TCGA数据库中NUSAP1 mRNA在浆液性卵巢癌中相对于正常卵巢组织高表达(P<0.05)。在FIGO分期III/IV期患者中NUSAP1蛋白高表达率显著高于Ⅰ/Ⅱ患者(P=0.009);G 2和G 3级患者中NUSAP1蛋白高表达率显著高于G 1级患者(P=0.034);存在腹水的患者中NUSAP1蛋白表达水平高于无腹水患者(P=0.012)。NUSAP1蛋白高表达患者较低表达患者总生存期更短(P=0.016)。多因素Cox回归分析显示NUSAP1是浆液性卵巢癌不良预后的独立危险因素(P=0.021)。结论:NUSAP1过表达可促进浆液性卵巢癌的发生及进展。NUSAP1可作为浆液性卵巢癌不良预后的预测因子及潜在治疗靶点。
Objective:To investigate the expression of NUSAP1 and evaluate the relationship between NUSAP1 expression and clinicopathological characteristics and prognosis of ovarian serous carcinoma(OSC).Methods:The mRNA expression of NUSAP1 was analyzed using TCGA database and further detected by immunohistochemistry in 115 OSC and 62 normal ovary tissues.The prognostic roles of NUSAP1 mRNA in ovarian cancer patients were analyzed by Kaplan-Meier plotter online database.Cox's proportional hazards regression model was used to analyze the survival data of OSC.Results:NUSAP1 mRNA in OSC was higher than that in normal ovary tissues in TCGA database(P<0.05).A high level of NUSAP1 expression significantly correlated with advanced-stage tumors(FIGO classes III-IV,P=0.009),high-grade carcinoma(grades 2-3,P=0.034)and malignant ascites(P=0.012).The patients with high expression of NUSAP1 had a worse overall survival than the patients with low expression of NUSAP1(log-rank test,P=0.016).A multivariate Cox model demonstrated that NUSAP1 is an independent prognostic indicator(P=0.021).Conclusion:High expression of NUSAP1 may be involved in OSC progression.Increased NUSAP1 expression is an independent factor of poor prognosis and may serve as a potential therapeutic target in OSC.
作者
周红菊
周敏
Zhou Hongju;Zhou Min(Department of Gynaecology and Obstetrics,Traditional Chinese Medicine Hospital of Pucheng,Shaanxi Weinan 715500,China;Department of Gynecologic Oncology,Shaanxi Provincial Tumor Hospital,Shaanxi Xi'an 710061,China)
出处
《现代肿瘤医学》
CAS
2019年第16期2913-2917,共5页
Journal of Modern Oncology